Home > Oncology > ELCC 2022 > Small Cell Lung Cancer > Total metabolic tumour volume: a new potential prognostic factor in SCLC

Total metabolic tumour volume: a new potential prognostic factor in SCLC

Presented By
Dr Elisa Andrini, Sant'Orsola-Malpighi University Hospital, Italy
Presented by
Elisa Andrini Sant'Orsola-Malpighi University Hospital, Italy
Conference
ELCC 2022
Doi
https://doi.org/10.55788/307829be
In patients with small cell lung cancer (SCLC), total metabolic tumour volume at baseline correlated with progression-free survival (PFS) and overall survival (OS) on first-line treatment in preliminary results from a retrospective study. The introduction of chemoimmunotherapy as first-line therapy for extensive-stage (ES-) SCLC has only improved the survival of a limited number of patients, highlighting the importance to predict treatment susceptibility. 18FDG-PET/CT is commonly used for the staging of SCLC and derived metabolic parameters could predict patient outcomes by measuring the extension of metabolically active tumour (metabolic tumour volume [MTV]) or its metabolic heterogeneity (total lesion glycolysis [TLG]). Italian investigators evaluated whether these parameters derived from 18FDG-PET are predictive of patient outcomes. Dr Elisa Andrini (Sant'Orsola-Malpighi University Hospital, Italy) presented the results [1].


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on